MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report
MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report
复制标题
DOI：
10.1590/s0004-27302012000800015
复制
发表时间：
2012-11-01
期刊：
影响因子：
--
通讯作者：
Kimura, Edna Teruko
中科院分区：
文献类型：
--
作者：
Geraldo, Murilo Vieira;Fuziwara, Cesar Seigi;Kimura, Edna Teruko
甲状腺乳头状癌（PTC）是甲状腺癌中最常见的组织学类型。一定比例的PTC病例（5%）对常规治疗无反应，放射性碘治疗无效。目前侵袭性的预后因素主要基于肿瘤大小、淋巴结转移的存在、甲状腺外浸润以及最近BRAFT（1799 A）突变的存在。微小RNA（miRNAs）已被描述为癌症的有前途的分子标记物，因为在广泛的肿瘤中观察到它们的失调。最近的研究表明miR-146 b-5 p的过表达与侵袭性和BRAFT（1799 A）突变相关。此外，在包括PTC在内的几种类型的肿瘤中观察到let-7 f的下调。在这项研究中，我们评估了一名年轻男性患者的miR 146 b-5 p和let-7 f状态，该患者患有侵袭性BRAFT（1799 A）阳性乳头状甲状腺癌，伴有广泛淋巴结转移和短期复发。miR-146 b-5 p和let-7 f表达分析揭示了PTC患者队列的独特模式，提示在评估miRNA表达数据作为PTC诊断和预后的分子标志物时应谨慎。Arq布拉斯内分泌代谢2012;56（8）：552-7
Papillary thyroid cancer (PTC) is the most incident histotype of thyroid cancer. A certain fraction of PTC cases (5%) are irresponsive to conventional treatment, and refractory to radioiodine therapy. The current prognostic factors for aggressiveness are mainly based on tumor size, the presence of lymph node metastasis, extrathyroidal invasion and, more recently, the presence of the BRAFT(1799A) mutation. MicroRNAs (miRNAs) have been described as promising molecular markers for cancer as their deregulation is observed in a wide range of tumors. Recent studies indicate that the over-expression of miR-146b-5p is associated with aggressiveness and BRAFT(1799A) mutation. Furthermore, down-regulation of let-7f is observed in several types of tumors, including PTC. In this study, we evaluated the miR146b-5p and let-7f status in a young male patient with aggressive, BRAFT(1799A)-positive papillary thyroid carcinoma, with extensive lymph node metastases and short-time recurrence. The analysis of miR-146b-5p and let-7f expression revealed a distinct pattern from a cohort of PTC patients, suggesting caution in evaluating miRNA expression data as molecular markers of PTC diagnosis and prognosis. Arq Bras Endocrinol Metab. 2012;56(8):552-7